Comparative Pharmacology
Head-to-head clinical analysis: ALLEGRA HIVES versus PBZ SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLEGRA HIVES versus PBZ SR.
ALLEGRA HIVES vs PBZ-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a non-sedating antihistamine (H1-receptor antagonist) that selectively inhibits peripheral H1 receptors, reducing histamine-mediated symptoms such as pruritus, urticaria, and vasodilation. It does not cross the blood-brain barrier significantly, minimizing CNS effects.
Antihistamine; H1-receptor antagonist that competes with histamine for binding at H1 receptor sites, thereby preventing histamine-mediated allergic responses.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
100-200 mg orally every 12 hours; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours). This supports once-daily dosing in most patients; however, in moderate to severe renal impairment, half-life may be prolonged (e.g., ~22 hours), necessitating dosing adjustment.
Terminal elimination half-life is approximately 4-6 hours in adults with normal renal function; clinically relevant dosing every 4-6 hours is recommended.
Fexofenadine is primarily excreted unchanged in feces (80%) and urine (11%). The remainder undergoes minimal hepatic metabolism. Renal elimination accounts for about 11% of the dose.
Primarily renal excretion (80-90% as unchanged drug) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 5-10%.
Category C
Category C
Antihistamine
Antihistamine